Izvorni znanstveni članak
Incidence and mortality trends of leukemia and lymphoma in Croatia, 1988-2009
Ina Novak
; Andrija Štampar School of Public Health, University of Zagreb Medical School, Zagreb, Croatia
Ozren Jakšić
; Department of Hematology Dubrava University Hospital, Zagreb, Croatia
Tomislav Kuliš
; Department of Urology, University Hospital Centre Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia
Katarina Batinjan
; Andrija Štampar School of Public Health, University of Zagreb Medical School, Zagreb, Croatia
Ariana Znaor
; Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia
Sažetak
Aim To investigate the time trends of leukemia and lymphoma
in Croatia from 1988-2009, compare them with
trends in other populations, and identify possible changes.
Methods The data sources were the Croatian National
Cancer Registry for incidence data, Croatian Bureau of Statistics
for the numbers of deaths, and United Nations population
estimates. Joinpoint regression analysis using the
age-standardized rates was used to analyze incidence and
mortality trends.
Results Acute lymphoblastic leukemia and chronic lymphocytic
leukemia incidence did not significantly change.
Acute myeloid leukemia incidence significantly increased
in women, with estimated annual percentage change
(EAPC) of 2.6% during the whole period, and in men since
1998, with EAPC of 3.2%. Chronic myeloid leukemia incidence
significantly decreased in women (EAPC -3.7%) and
remained stable in men. Mortality rates were stable for
both lymphoid and myeloid leukemia in both sexes. Hodgkin
lymphoma non-significantly increased in incidence
and significantly decreased in mortality (EAPCs of -5.6% in
men and -3.7% in women). Non-Hodgkin lymphoma significantly
increased in incidence in women (EAPC 3.2%)
and non-significantly in men and in mortality in both men
(EAPC 1.6%) and women (EAPC 1.8%).
Conclusion While Croatia had similar leukemia and lymphoma
incidence trends as the other countries, the mortality
trends were less favorable than in Western Europe.
The lack of declines of leukemia incidence and non-Hodgkin
lymphoma mortality could be attributed to late introduction
of optimal therapies. As currently the most up-todate
diagnostics and treatments are available and covered
by health insurance, we expect more favorable trends in
the future.
Ključne riječi
Hrčak ID:
83866
URI
Datum izdavanja:
15.4.2012.
Posjeta: 1.259 *